Before a Sermorelin prescription
A request starts a conversation. I would want three things explained before it goes further: the problem being assessed, the medicine being considered and what happens after the decision.
Check 1
What problem are we trying to solve?
This is where I'd begin, even if Sermorelin was the name that caught your attention. Its former treatment approval was for children with growth failure linked to growth hormone deficiency. That didn't establish an adult treatment for tiredness, sleep or body shape.
A prescriber needs to consider the person making the request. Questions about your history, medicines and reasons for seeking care belong here. A general guide can't diagnose a deficiency or decide whether you qualify.
I would also ask why this medicine is being considered over other approaches. More assessment, another treatment or no medicine can all be part of the discussion. A clear explanation is useful even when the answer isn't the one you expected.
The history and adult studies give you context for that conversation. They don't decide its outcome.
Supporting reading The review of earlier use in childrenCheck 2
Who makes the medicine, and what is it?
Compounded drugs are not FDA-approved; FDA does not verify their safety, effectiveness or quality before they are marketed. Having a prescription doesn't change that distinction.
Patient-specific compounding generally involves a prescription for an identified person, with other rules applying too. Under FDA's ingredient guidance, an ingredient's history as part of an approved drug may be relevant. For Sermorelin acetate, that may provide a route under the compounding rules if all the conditions are met.
It isn't blanket permission for every product. The form of the ingredient and the particular preparation matter. An old approval doesn't become a new one by following the name.
My practical questions are simpler: who prepares it, what is in it, and how can the pharmacy's licence be checked? A website accepting a request doesn't answer those questions on its own.
Supporting reading FDA on what compounding meansCheck 3
Who reviews what happens next?
The small older-men study found higher growth hormone and IGF-1, a related growth factor measured in blood. It didn't establish lasting improvements in everyday health. I would ask what benefit is being sought beyond a changed number.
Safety belongs in the same conversation. FDA's wider hormone-risk discussion includes blood-sugar problems and fluid retention. Those are class concerns, not a Sermorelin risk estimate for you.
What would count as a useful improvement? Who evaluates unwanted effects, and what could change the plan? Those are questions for the clinician, not a monitoring schedule from this page.
For unclear amounts or label directions, the prescriber and dispensing pharmacist are the contacts who can review the actual preparation. The dosage page explains why a general conversion can't replace that answer. A request still leaves room for a decision against treatment.
Supporting reading The two-week hormone study in older men